The tolerability number that will follow petrelintide into every Phase 3 negotiation is 1.5% — the share of participants who discontinued the drug due to gastrointestinal adverse events across the 42-week ZUPREME-1 trial. In a therapeutic class where GI burden drives real-world dropout, that figure is the sharpest edge in the dataset Zealand Pharma presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans.
The Phase 2 trial enrolled 485 adults with a mean BMI of 36.7 kg/m² and randomized them 5:1 across five once-weekly subcutaneous doses of petrelintide, an amylin analog, versus placebo. At week 42, the highest-performing arm achieved 10.7% mean body weight reduction versus 1.7% for placebo — double-digit loss that cleared the primary endpoint at week 28 with statistical significance across all five arms. What distinguishes the profile is where the GI signal lands: nausea occurred in 19.6% of petrelintide participants versus 6.2% on placebo, but vomiting came in at 3.0% versus 6.2% for placebo — lower on active treatment — and more than 75% of all GI events were mild. Between 88% and 98% of participants successfully escalated to their target maintenance dose, a dose-escalation completion rate that most obesity trials would envy. The cardiometabolic secondary data add a further layer: waist circumference fell 7.9–10.8 cm versus 4.3 cm on placebo, high-sensitivity CRP dropped 17–41% versus 6%, and triglycerides fell 12–21% versus 9%.
The competitive context matters here. Wegovy received FDA approval in June 2021 and Zepbound followed in November 2023, both targeting the incretin axis. Eli Lilly’s retatrutide, a triple agonist, posted 28.3% weight loss at the highest dose in Phase 3 TRIUMPH-1 results released in May 2026. Against that backdrop, petrelintide’s 10.7% looks modest in absolute terms — but it arrives via a mechanistically distinct amylin pathway, and the GI tolerability argument is explicit: real-world persistence on current therapies is the acknowledged problem petrelintide is designed to solve. Roche and Zealand formally endorsed Phase 3 advancement in April 2026, with initiation planned for the second half of this year.
The number to track as Phase 3 launches is not peak weight loss — it is treatment discontinuation rate due to GI events at the trial’s primary timepoint. If 1.5% holds anywhere near that floor in a larger, longer, more diverse population, Zealand and Roche have a durable differentiator regardless of where efficacy lands relative to the incretin class.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
